Mark Massaro

BTIG | Healthcare

Mark Massaro is an analyst from BTIG specializing in the Healthcare sector. Ranked #1212 out of 4565 analysts, they have issued 53 stock ratings with a success rate of 91.81% and an average return of 11.14%.

Mark Massaro has a well-established track record, with 53 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 91.81% and an average return of 11.14%, underscoring their expertise and ability to identify winning opportunities for investors.

#1212

Out of 4565

53

Total Ratings

+91.81%

Success Rate

+11.14%

Average Return

Recent Ratings Analysis

BLLN

Mar 05, 2026

Target

$160.00

Current

$83.14

Performance

%

Mark Massaro rated BLLN as Buy on Mar 05, 2026, setting a price target of 160. Shares have remained stable near 83.14, leaving the 160 target still in play.

CAI

Feb 27, 2026

Target

$45.00

Current

$19.38

Performance

-3.77%

On Feb 27, 2026, CAI was given a Buy rating by Mark Massaro, with a target price of 45. The stock traded sideways with a -3.77% move, keeping the bullish thesis unresolved.

CDNA

Feb 26, 2026

Target

$26.00

Current

$18.80

Performance

-0.11%

CDNA received a Buy rating from Mark Massaro on Feb 26, 2026, aiming for 26. Price action was muted, as shares hovered around 18.8 despite the bullish outlook.

TEM

Feb 25, 2026

Target

$105.00

Current

$51.40

Performance

-4.30%

On Feb 25, 2026, Mark Massaro published a Buy outlook on TEM, with a target of 105. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 51.4.

WGS

Feb 24, 2026

Target

$200.00

Current

$76.97

Performance

-4.62%

Mark Massaro on Feb 24, 2026 assigned WGS a Buy rating, with a price target of 200. The recommendation remains pending validation as shares consolidate around 76.97.

GH

Feb 20, 2026

Target

$145.00

Current

$93.30

Performance

-9.51%

On Feb 20, 2026, Mark Massaro reaffirmed GH with a Buy rating, targeting 145. Shares slid 9.51% despite the recommendation, highlighting downside risks.

XGN

Feb 17, 2026

Target

$15.00

Current

$3.43

Performance

3.63%

XGN was rated Buy by Mark Massaro on Feb 17, 2026, with a price objective of 15. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

PSNL

Feb 11, 2026

Target

$13.00

Current

$8.67

Performance

-2.58%

On Feb 11, 2026, Mark Massaro initiated coverage on PSNL with a Buy rating and target of 13. Neutral price movement of -2.58% leaves room for interpretation.

ADPT

Feb 06, 2026

Target

$22.00

Current

$16.08

Performance

1.97%

Mark Massaro issued a Buy recommendation for ADPT on Feb 06, 2026, price target set at 22. The target of 22 remains in play, though confirmation will depend on future moves.

IDXX

Feb 03, 2026

Target

$800.00

Current

$635.54

Performance

0.47%

On Feb 03, 2026, IDXX was evaluated by Mark Massaro, who gave a Buy rating and target of 800. So far, the Buy call awaits clearer momentum, with shares flat at 635.54.

MDXH

Dec 23, 2025

Target

$7.00

Current

$3.35

Performance

-3.46%

Mark Massaro rated MDXH as Buy on Dec 23, 2025, setting a price target of 7. Shares have remained stable near 3.35, leaving the 7 target still in play.

CSTL

Dec 12, 2025

Target

$50.00

Current

$27.57

Performance

-28.63%

On Dec 12, 2025, CSTL was given a Buy rating by Mark Massaro, with a target price of 50. Despite the Buy call, shares fell from 27.57 to 27.57, challenging the optimistic stance.

NTRA

Dec 05, 2025

Target

$260.00

Current

$207.04

Performance

-15.34%

NTRA received a Buy rating from Mark Massaro on Dec 05, 2025, aiming for 260. The rating hasn’t played out as hoped, with the stock trading 15.34% below expectations.

ZTS

Dec 03, 2025

Target

$160.00

Current

$125.93

Performance

2.74%

On Dec 03, 2025, Mark Massaro published a Buy outlook on ZTS, with a target of 160. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 125.93.

EXAS

Nov 20, 2025

Target

$0.00

Current

$103.37

Performance

2.68%

Mark Massaro on Nov 20, 2025 assigned EXAS a Neutral rating, with a price target of null. The Hold stance reflected consolidation, as shares held near 103.37.

SOPH

Nov 10, 2025

Target

$7.00

Current

$4.10

Performance

-5.75%

On Nov 10, 2025, Mark Massaro reaffirmed SOPH with a Buy rating, targeting 7. Shares slid 5.75% despite the recommendation, highlighting downside risks.

LUCD

Sep 10, 2025

Target

$2.50

Current

$1.45

Performance

42.16%

LUCD was rated Buy by Mark Massaro on Sep 10, 2025, with a price objective of 2.5. A bullish response from the market helped close the gap of 1.05 to the target.

DNA

Aug 25, 2025

Target

$9.00

Current

$6.70

Performance

-44.40%

On Aug 25, 2025, Mark Massaro initiated coverage on DNA with a Sell rating and target of 9. Shares gained despite the bearish call, moving higher from 6.7.

MXCT

Aug 11, 2025

Target

$0.00

Current

$0.76

Performance

-42.41%

Mark Massaro issued a Neutral recommendation for MXCT on Aug 11, 2025, price target set at null. Market action validated the conservative Hold outlook with shares at 0.7602.

AKYA

May 14, 2024

Target

$6.00

Current

$1.29

Performance

-55.52%

On May 14, 2024, AKYA was evaluated by Mark Massaro, who gave a Buy rating and target of 6. Investors saw limited payoff as shares fell short of the 6 target.

NEO

May 02, 2024

Target

$21.00

Current

$9.54

Performance

-35.19%

Mark Massaro rated NEO as Buy on May 02, 2024, setting a price target of 21. The stock has underperformed, dropping 35.19% despite the bullish target of 21.

Frequency Asked Questions

Who is Mark Massaro?

Mark Massaro is an analyst from BTIG specializing in the Healthcare sector.

What is Mark Massaro's success rate?

Mark Massaro currently has a success rate of +91.81%.

How many ratings has Mark Massaro issued?

Mark Massaro has issued 53 stock ratings so far.

What is the average return of Mark Massaro's calls?

Their stock ratings have generated an average return of +11.14%.

What is Mark Massaro's ranking?

Mark Massaro is ranked #1212 out of 4565 analysts.

What types of ratings does Mark Massaro give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Mark Massaro?

You can follow Mark Massaro by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Mark Massaro?

Their latest rating was a Buy on BLLN issued on 2026-03-05.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep